Retrospective Evaluation of Metastasectomy and Systemic Treatment in Patients with Non-Small Cell Lung Cancer and Cranial Metastasis

Öz

The brain is one of the organs that non-small cell lung cancer (NSCLC) metastasizes most frequently. The life expectancy is limited to months in patients with brain metastasis (BM), which is not treated. This study aims to show the oncological outcomes of surgical treatment of cranial lesion in patients with stage 4 NSCLC. The data of 59 patients who were diagnosed with NSCLC and underwent surgical treatment of BM between 2004 and 2012 in our clinic were prospectively recorded and analyzed retrospectively. The surgical and oncological out-comes of the patients were studied. Survival was calculated as the time between the diagnosis of BM and the date of death or the last follow-up. Fifty-one of the patients were male, and eight were female, and the median age was 56.9 (37-81) years. Fifty-five patients underwent total excision, and four patients underwent subtotal excision. No postoperative mortality was detected. As a result of the pathological exami-nation, the surgical margins were reported as tumor-free in 55 patients, and microscopically positive in 4 patients. Palliative cranial radio-therapy and systemic chemotherapy were given to all patients after surgery. Eleven patients (18.6%) underwent chemoradiotherapy to the primary mass in the lung. Lobectomy and pneumonectomy were performed in 8 and 7 patients. The median overall survival was 12.00 (1.0-159.0) months. The 12, 24, and 60-month survival rates of the patients were 47.5%, 28.8%, and 13.5%, respectively. In three cases, overall survival over ten years was obtained. Cranial metastasectomy may contribute positively to the survival of patients with NSCLC.

Anahtar Kelimeler

• lung cancer,, cranial metastasis

Küçük Hücreli Dışı Akciğer Kanserli Kranial Metastaz Gelişen Olgularda Metastazektomi Yapılan ve Sistemik Tedavi Alan Hastaların Retrospektif Değerlendirilmesi

Öz

Küçük hücreli dışı akciğer kanseri (KHDAK)’nin en sık metastaz yaptığı organlardan biri beyindir. Beyin metastazı olan hastalar tedavi edilmediğinde ortalama yaşam süresi aylarla sınırlıdır. Bu çalışmanın amacı beyin metastazı yapmış evre 4 KHDAK hastalarda beyin metastazı için cerrahi tedavi uygulamasının onkolojik sonuçlarını göstermektir. Kliniğimizde 2004-2012 yılları arasında KHDAK tanısı konan ve BM nedeniyle cerrahi tedavi uygulanan 59 hastanın verileri prospektif olarak kaydedildi ve retrospektif olarak incelendi. Hastaların cerrahi ve onkolojik sonuçları irdelendi. Sağ kalım süresi beyin metastazı tanısı konulduğu tarih ile ölüm tarihi veya mevcut en son takip arasındaki zaman olarak hesaplandı. Hastaların 51’i erkek, 8’i kadın, ortalama yaş 56.92 (37-81) yıl idi. Cerrahi olarak 55 hastaya total eksizyon, 4 hastaya subtotal eksizyon yapıldı. Ameliyat sonrası mortalite saptanmadı. Patolojik inceleme sonucunda 55 hastada cerrahi sınırlar tümörsüz, 4 hastada ise cerrahi sınır mikroskobik pozitif olarak bildirildi. Ameliyat sonrasında tüm hastalara palyatif kranial radyoterapi ve sistemik kemoterapi verildi. 11 hastaya(%18,6) akciğerdeki primer kitleye kemoradyoterapi verildi. 8 hastaya akciğere yönelik cerrahi lobektomi, 7 hastaya pnömonektomi uygulandı. Medyan genel sağkalım süresi 12,00 (1,0-159,0) aydı. Hastaların 12, 24 ve 60 aylık sağkalım oranları sırasıyla %47.5, %28.8 ve %13.5 olarak bulundu. Üç olguda ise 10 yılın üzerinde genel sağ kalım elde edildi. Beyin metastazı yapmış KHDAK’lu hastalarda kranial metastazektomi hastaların sağkalımına olumlu katkı sağlayabilir.

Anahtar Kelimeler

• akciğer kanseri,beyin metastazı

Kaynakça

1. 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30.
2. 2. Bovi J.A., White J. Radiation therapy in the prevention of brain metastases. Curr. Oncol. Rep. 2012;14:55–62
3. 3. Sperduto PW, Chao ST, Sneed PK et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):655-61
4. 4. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23:6207‑19.
5. 5. Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993 Jun;33(6):583-90.
6. 6. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884‑98.
7. 7. Bonnette P, Puyo P, Gabriel C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 2001;119:1469-75.
8. 8. Getman V, Devyatko E, Dunkler D, et al. Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment. Eur J Cardiothorac Surg 2004;25:1107-13.

9. 9. Billing PS, Miller DL, Allen MS, et al. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 2001;122:548-53.
10. 10. Mussi A, Pistolesi M, Lucchi M, et al. Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors. J Thorac Cardiovasc Surg 1996;112:146-53.
11. 11. Inal A, Kodaz H, Odabas H, et al.Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology). J Cancer Res Ther. 2018 Apr-Jun;14(3):578-82
12. 12. Bonnette P, Puyo P, Gabriel C, et al. Groupe Thorax. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest. 2001 May;119(5):1469-75.
13. 13. Niemiec M, Głogowski M, Tyc-Szczepaniak D, Wierzchowski M, Kępka L. Characteristics of long-term survivors of brain metastases from lung cancer. Rep Pract Oncol Radiother. 2011 Feb 1;16(2):49-53.
14. 14. Iwasaki A, Shirakusa T, Yoshinaga Y, Enatsu S, Yamamoto M. Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. Eur J Cardiothorac Surg. 2004 Sep;26(3):488-93.
15. 15. Saito EY, Viani GA, Ferrigno R, et al. Whole brain radiation therapy in management of brain metastasis: results and prognostic factors. Radiat Oncol 2006;1:20.
16. 16. Arbit E, Wroński M, Burt M, Galicich JH. The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with nonsmall cell lung cancer. Cancer 1995;76(5):765-73.
17. 17. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park) 1999;13(7):941-54, 957-69.
18. 18. Peters S, Camidge DR, Shaw AT et al. ALEX Trial Investigators. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Aug 31;377(9):829-38.
19. 19. Yang JC, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51.
20. 20. Gadgeel S, Peters S, Mok T et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 Nov 1;29(11):2214-22.